CRSP (CRISPR Therapeutics AG) Tariff Resilience Score: 7/10 (As of Jul. 08, 2026)


CRSP CRISPR Therapeutics AG CRSP
41 GF Score
Price $59.10
GF Value $2.88
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CRISPR Therapeutics AG Tariff Resilience Score?

CRISPR Therapeutics AG CRSP -2.75% 41 Tariff Resilience Score is 7 as of Jul. 08, 2026. GuruFocus rates CRSP with a GF Score™ of 41/100 and a GF Value™ of $2.88 (Significantly Overvalued). The stock has 4 warning signs investors should review. Among 1,367 Biotechnology companies, CRISPR Therapeutics AG ranks better than 90.34% on this metric.

CRISPR Therapeutics AG has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

CRISPR Therapeutics AG has CRISPR Therapeutics has moderate exposure to tariffs due to its international research and development activities. However, its focus on biotech reduces direct impact from traditional trade tariffs.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes CRISPR Therapeutics AG might have Highly Resilient.

CRISPR Therapeutics AG  (NAS:CRSP) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

CRISPR Therapeutics AG Tariff Resilience Score Related Terms

CRSP vs ORKA, TVTX, MANE: Tariff Resilience Score Comparison

For the Biotechnology subindustry, CRISPR Therapeutics AG's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

CRISPR Therapeutics AG Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CRISPR Therapeutics AG's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where CRISPR Therapeutics AG's Tariff Resilience Score falls into.


CRSP
41GF Score
CRISPR Therapeutics AG CRSP
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
CRISPR Therapeutics AG (CRSP) has a Tariff Resilience Score of 7 as of Jul. 08, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, CRISPR Therapeutics AG ranks #132 out of 1367 companies in the Biotechnology industry, placing it in the top 9.7%.
Is CRISPR Therapeutics AG's Tariff Resilience Score too high?
CRISPR Therapeutics AG's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. CRISPR Therapeutics AG's value of 7 is 75% above this industry median. Based on the distribution chart, CRISPR Therapeutics AG ranks #132 out of 1367 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, CRISPR Therapeutics AG has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CRISPR Therapeutics AG's Tariff Resilience Score compare to ORKA and TVTX?
According to the Biotechnology industry distribution chart, CRISPR Therapeutics AG ranks #132 out of 1367 companies for Tariff Resilience Score. This places CRISPR Therapeutics AG in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. CRISPR Therapeutics AG's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,367 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CRISPR Therapeutics AG's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CRISPR Therapeutics AG's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CRISPR Therapeutics AG stock overvalued right now?
Based on GuruFocus' analysis, CRISPR Therapeutics AG (CRSP) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.88, compared to a current price of $59.10 — trading 1952.1% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. CRISPR Therapeutics AG's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For CRISPR Therapeutics AG (CRSP), the current Tariff Resilience Score is 7 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CRISPR Therapeutics AG (CRSP) Overvalued in 2026?

Based on GuruFocus' analysis, CRISPR Therapeutics AG stock appears to be overvalued. The current stock price of $59.10 is trading 1952.1% above its estimated GF Value™ of $2.88. GuruFocus considers CRISPR Therapeutics AG to be Significantly Overvalued.

Key valuation signals for CRSP:

  • Tariff Resilience Score: 7
  • GF Value™: $2.88 vs. price of $59.10 (1952.1% above fair value)
  • GF Score™: 41/100 with 4 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1367)

No single metric tells the full story. See the CRSP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CRISPR Therapeutics AG Business Description

Address Baarerstrasse 14, Zug, CHE, 6300
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
41GF Score

Get the complete analysis for CRSP

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$59.10
Price
$2.88
GF Value